PharVision Advisers’s Lamb Weston LW Stock Holding History

PharVision Advisers’s Portfolio LW Stock Details LW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,042	Closed	-$337K	–	412
2025 Q4	$337K	Buy	+8,042	New	+$473K	0.17%	217

Other funds holding LW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Starboard Value New York $4.52B AUM 19.34% 1-Year Est. Return

JPM

JANA Partners Management New York $1.9B AUM 18.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CGC

Continental Grain Company New York $448M AUM 6.81% 1-Year Est. Return

PharVision Advisers's LW Position: Q1 2026 in Review

PharVision Advisers sold out of Lamb Weston (LW) in Q1 2026, closing a stake of 8,042 shares — an estimated $337K sold.

PharVision Advisers first reported a position in LW in Q4 2025 and held it in 1 quarter. The position peaked at $337K in Q4 2025. 566 funds tracked by Wall St. Rank hold LW as of Q1 2026.

PharVision Advisers reported no remaining Lamb Weston position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 8,042 Lamb Weston shares in Q1 2026, an estimated $337K.
PharVision Advisers first reported a position in Lamb Weston in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Lamb Weston position peaked at $337K in Q4 2025.
566 funds tracked by Wall St. Rank held Lamb Weston as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.